Noninvasive determinants of pulmonary hypertension in interstitial lung disease

被引:12
|
作者
Joseph, Phillip [1 ,5 ]
Savarimuthu, Stella [1 ]
Zhao, Jiayi [2 ]
Yan, Xiting [1 ]
Oakland, Hannah T. [1 ]
Cullinan, Marjorie [3 ]
Heerdt, Paul M. [4 ]
Singh, Inderjit [1 ]
机构
[1] Yale New Haven Hosp, Yale Sch Med, Dept Med, Div Pulm, New Haven, CT 06520 USA
[2] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[3] Yale New Haven Hosp, Dept Resp Care, New Haven, CT USA
[4] Yale New Haven Hosp, Yale Sch Med, Dept Anaesthesiol, New Haven, CT USA
[5] Yale New Haven Hosp, Yale Sch Med, Dept Med, Div Pulm, New Haven, CT 06511 USA
关键词
cardiopulmonary exercise testing; interstitial lung disease; pulmonary hypertension; NATRIURETIC PEPTIDE LEVELS; INHALED TREPROSTINIL; EXERCISE; VENTILATION; PRESSURE; OBESITY; IMPACT;
D O I
10.1002/pul2.12197
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) in interstitial lung disease (ILD) is associated with increased mortality and impaired exertional capacity. Right heart catheterization is the diagnostic standard for PH but is invasive and not readily available. Noninvasive physiologic evaluation may predict PH in ILD. Forty-four patients with PH and ILD (PH-ILD) were compared with 22 with ILD alone (non-PH ILD). Six-min walk distance (6MWD, 223 +/- 131 vs. 331 +/- 125 m, p = 0.02) and diffusing capacity for carbon monoxide (DLCO, 33 +/- 14% vs. 55 +/- 21%, p < 0.001) were lower in patients with PH-ILD. PH-ILD patients exhibited a lower gas-exchange derived pulmonary vascular capacitance (GX(CAP), 251 +/- 132 vs. 465 +/- 282 mL x mmHg, p < 0.0001) and extrapolated maximum oxygen uptake (VO2max) (56 +/- 32% vs. 84 +/- 37%, p = 0.003). Multivariate analysis was performed to determine predictors of VO2max. GX(CAP) was the only variable that predicted extrapolated VO2max among PH-ILD and non-PH ILD patients. Receiver operating characteristic curve analysis assessed the ability of individual noninvasive variables to distinguish between PH-ILD and non-PH ILD patients. GX(CAP) (area under the curve [AUC] 0.85 +/- 0.04, p < 0.0001) and delta ETCO2 (AUC 0.84 +/- 0.04, p < 0.0001) were the strongest predictors of PH-ILD. A CART analysis selected GX(CAP), estimated right ventricular systolic pressure (eRVSP) by echocardiogram, and FVC/DLCO ratio as predictive variables for PH-ILD. With this analysis, the AUC improved to 0.94 (sensitivity of 0.86 and sensitivity of 0.93). Patients with a GX(CAP) <= 416 mL x mmHg had an 82% probability of PH-ILD. Patients with GX(CAP) <= 416 mL x mmHg and high FVC/DLCO ratio >1.7 had an 80% probability of PH-ILD. Patients with GX(CAP) <= 416 mL x mmHg and an elevated eRVSP by echocardiogram >43 mmHg had 100% probability of PH-ILD. The incorporation of GX(CAP) with either eRVSP or FVC/DLCO ratio distinguishes between PH-ILD and non-PH-ILD with high probability and may therefore assist in determining the need to proceed with a diagnostic right heart catheterization and potential initiation of pulmonary arterial hypertension-directed therapy in PH-ILD patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
    Lawrence, Alexandra
    Myall, Katherine Jane
    Mukherjee, Bhashkar
    Marino, Philip
    LIFE-BASEL, 2024, 14 (09):
  • [32] Autoantibodies and Pulmonary Hypertension by Echocardiography in Patients with Interstitial Lung Disease
    Selvan, K.
    Boise, J.
    Hershey, E.
    Nurhussien, L. A.
    Ngo, D.
    Rice, M. B.
    Hallowell, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [33] Pulmonary Hypertension in Interstitial Lung Disease: Ege University Experience
    Mogulkoc, Nesrin
    Nesil, Imren
    Demir, Emre
    Kultursay, Hakan
    Akdeniz, Bahri
    Bayraktaroglu, Selen
    Koc, Aysu
    CHEST, 2016, 150 (04) : 1178A - 1178A
  • [34] Optimism for Interstitial Lung Disease-Associated Pulmonary Hypertension?
    Taichman, Darren B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (04): : 376 - 377
  • [35] Scleroderma patients with combined pulmonary hypertension and interstitial lung disease
    Chang, B
    Wigley, FM
    White, B
    Wise, RA
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (11) : 2398 - 2405
  • [36] Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
    Waxman, Aaron
    Restrepo-Jaramillo, Ricardo
    Thenappan, Thenappan
    Ravichandran, Ashwin
    Engel, Peter
    Bajwa, Abubakr
    Allen, Roblee
    Feldman, Jeremy
    Argula, Rahul
    Smith, Peter
    Rollins, Kristan
    Deng, Chunqin
    Peterson, Leigh
    Bell, Heidi
    Tapson, Victor
    Nathan, Steven D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (04): : 325 - 334
  • [37] Specific therapy for pulmonary hypertension in patients with interstitial lung disease
    Tueller, C.
    Krebser, S.
    Geiser, T.
    SWISS MEDICAL WEEKLY, 2010, 140 (13-14) : 12S - 12S
  • [38] Cyclosporine A for treatment of interstitial lung disease and pulmonary hypertension.
    Kelsall, JT
    Chalmers, A
    Rangno, K
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1404 - 1404
  • [39] Recent advances in the management of pulmonary hypertension with interstitial lung disease
    Waxman, Aaron B.
    Elia, Davide
    Adir, Yochai
    Humbert, Marc
    Harari, Sergio
    EUROPEAN RESPIRATORY REVIEW, 2022, 31 (165):
  • [40] Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
    Melendres-Groves, Lana
    Vazquez-Guillamet, Rodrigo
    Dhillon, Gundeep
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2015, 11 (02) : 156 - 162